Nuon Therapeutics, Inc.

Nuon Therapeutics To Present Update On Programs In Rheumatoid Arthritis and Gout at 2010 BIO International Convention

San Mateo, CA, April 29, 2010 – Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced today that the company was selected and is scheduled to present at the 2010 BIO Business Forum during the BIO International Convention in Chicago (May 3-6, 2010). Nuon will provide a corporate overview including an update on its phase 2 program in rheumatoid arthritis (RA) and progress with advancing its lead program, NU1618, into phase 2b development for the treatment of chronic hyperuricemia in patients with gout. The presentation will be held on Thursday, May 6, 2010 at 10:45 AM Central time in Room 2 of McCormick Place.

About Nuon Therapeutics, Inc.

Nuon Therapeutics, Inc. is a privately held, clinical stage, biopharmaceutical company that develops innovative small molecule drugs that address critical, unmet medical needs in autoimmune and rheumatic diseases. The Company was founded in 2006 and has raised a total of $38 million from investors including Domain Associates, L.L.C., Frazier Healthcare Ventures, and GBS Venture Partners. Nuon Therapeutics, Inc. has its headquarters in San Mateo, CA. For additional information, please visit: www.nuontherapeutics.com

Contact: